Evidence map›Paper›PMID 30809221›Full record

ArticleFrontiers in immunology2019

Sialyllactose and Galactooligosaccharides Promote Epithelial Barrier Functioning and Distinctly Modulate Microbiota Composition and Short Chain Fatty Acid Production

Olaf Perdijk, Peter van Baarlen, Marcela M Fernandez-Gutierrez, Erik van den Brink, Frank H J Schuren, Sylvia Brugman, Huub F J Savelkoul, Michiel Kleerebezem, R J Joost van Neerven

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 125 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Effects of Pea (Nutrients · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Sialic acid plays a pivotal role in licensingProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Olaf PerdijkCell Biology and Immunology Group, Wageningen University & Research, Wageningen, Netherlands.
Peter van BaarlenHost-Microbe Interactomics Group, Wageningen University & Research, Wageningen, Netherlands.
Marcela M Fernandez-GutierrezHost-Microbe Interactomics Group, Wageningen University & Research, Wageningen, Netherlands.
Erik van den BrinkCell Biology and Immunology Group, Wageningen University & Research, Wageningen, Netherlands.
Frank H J SchurenMicrobiology and Systems Biology, The Netherlands Organization for Applied Scientific Research, Zeist, Netherlands.
Sylvia BrugmanCell Biology and Immunology Group, Wageningen University & Research, Wageningen, Netherlands.
Huub F J SavelkoulCell Biology and Immunology Group, Wageningen University & Research, Wageningen, Netherlands.
Michiel KleerebezemHost-Microbe Interactomics Group, Wageningen University & Research, Wageningen, Netherlands.
R J Joost van NeervenCell Biology and Immunology Group, Wageningen University & Research, Wageningen, Netherlands.
Wageningen University & Research · NLFrieslandCampina (Netherlands) · NLNetherlands Organisation for Applied Scientific Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human milk oligosaccharides (HMO) and prebiotic oligosaccharides are proposed to confer several health benefits to the infant. They shape the microbiota, have anti-inflammatory properties, and support epithelial barrier functioning. However, in order to select the best oligosaccharides for inclusion in infant formulas, there is a need to increase our understanding of the specific effects of HMO and prebiotics on the host immune system. Therefore, we investigated the effects of the HMO sialyllactose (SL), and galactooligosaccharides (GOS) on epithelial barrier functioning, microbiota composition, and SCFA production. The effect of GOS and SL on epithelial barrier functioning and microbiota composition was investigated using

Indexed as

Alkaline PhosphataseBacteroidesBifidobacteriumCaco-2 CellsCell CycleCell DifferentiationCell ProliferationFatty Acids, VolatileGastrointestinal MicrobiomeHumansInfantIntestinal MucosaLactoseMilk, HumanOligosaccharidesSialic AcidsAlkaline PhosphataseFatty Acids, VolatileLactoseN-acetylneuraminoyllactoseOligosaccharidesSialic Acidsepitheliumgalactooligosaccharidesmicrobiotashort chain fatty acidssialyllactose

Identifiers

PMID30809221
PMCPMC6380229
OpenAlexW2914777621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.